MA37748A1 - Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 - Google Patents

Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10

Info

Publication number
MA37748A1
MA37748A1 MA37748A MA37748A MA37748A1 MA 37748 A1 MA37748 A1 MA 37748A1 MA 37748 A MA37748 A MA 37748A MA 37748 A MA37748 A MA 37748A MA 37748 A1 MA37748 A1 MA 37748A1
Authority
MA
Morocco
Prior art keywords
azetidine
piperidine compounds
compounds useful
pde10 inhibitors
pde10
Prior art date
Application number
MA37748A
Other languages
English (en)
Other versions
MA37748B1 (fr
Inventor
Jennifer R Allen
Jian J Chen
Michael J Frohn
Matthew Richard Kaller
Qingyian Liu
Thomas T Nguyen
Alexander J Pickrell
Wenyuan Qian
Robert M Rzasa
Wenge Zhong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37748(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA37748A1 publication Critical patent/MA37748A1/fr
Publication of MA37748B1 publication Critical patent/MA37748B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés d'azétidine et de pipéridine de formule (i) tels que définis dans le descriptif, des compositions les contenant, et des procédés de préparation de ces composés et leurs intermédiaires. L'invention concerne également des méthodes de traitement des maladies ou troubles cognitifs pouvant être traités par inhibition de pde10, tels que la maladie de huntington, la schizophrénie, les troubles bipolaires, les troubles obsessionnels-compulsifs et analogue.
MA37748A 2012-06-14 2013-06-14 Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 MA37748B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14
PCT/US2013/045768 WO2013188724A1 (fr) 2012-06-14 2013-06-14 Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10

Publications (2)

Publication Number Publication Date
MA37748A1 true MA37748A1 (fr) 2016-11-30
MA37748B1 MA37748B1 (fr) 2017-07-31

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37748A MA37748B1 (fr) 2012-06-14 2013-06-14 Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10

Country Status (25)

Country Link
US (3) US8691986B2 (fr)
EP (1) EP2864317A1 (fr)
JP (1) JP2015519402A (fr)
KR (1) KR20150023417A (fr)
CN (1) CN104619694A (fr)
AP (1) AP2014008136A0 (fr)
AR (1) AR091436A1 (fr)
AU (1) AU2013274153B2 (fr)
BR (1) BR112014031368A2 (fr)
CA (1) CA2875802A1 (fr)
CL (1) CL2014003391A1 (fr)
CO (1) CO7160011A2 (fr)
CR (1) CR20150012A (fr)
EA (1) EA201590014A1 (fr)
HK (1) HK1203935A1 (fr)
IL (1) IL235901A0 (fr)
MA (1) MA37748B1 (fr)
MX (1) MX2014014924A (fr)
PE (1) PE20150348A1 (fr)
PH (1) PH12014502780A1 (fr)
SG (1) SG11201408168UA (fr)
TN (1) TN2014000510A1 (fr)
TW (1) TWI508959B (fr)
UY (1) UY34858A (fr)
WO (1) WO2013188724A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
US8946230B2 (en) * 2010-05-13 2015-02-03 Amgen Inc. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors
MX2012013127A (es) * 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
SG185515A1 (en) * 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Also Published As

Publication number Publication date
US9493459B2 (en) 2016-11-15
SG11201408168UA (en) 2015-01-29
JP2015519402A (ja) 2015-07-09
TN2014000510A1 (en) 2016-03-30
PE20150348A1 (es) 2015-03-04
AU2013274153A1 (en) 2014-12-18
MA37748B1 (fr) 2017-07-31
UY34858A (es) 2013-11-29
US20130338138A1 (en) 2013-12-19
US8691986B2 (en) 2014-04-08
WO2013188724A1 (fr) 2013-12-19
US20160176874A1 (en) 2016-06-23
CR20150012A (es) 2015-02-11
CO7160011A2 (es) 2015-01-15
IL235901A0 (en) 2015-09-24
TWI508959B (zh) 2015-11-21
AR091436A1 (es) 2015-02-04
MX2014014924A (es) 2015-03-09
CA2875802A1 (fr) 2013-12-19
TW201412729A (zh) 2014-04-01
EA201590014A1 (ru) 2015-04-30
KR20150023417A (ko) 2015-03-05
US9303028B2 (en) 2016-04-05
CN104619694A (zh) 2015-05-13
EP2864317A1 (fr) 2015-04-29
AU2013274153B2 (en) 2016-05-19
PH12014502780A1 (en) 2015-02-02
BR112014031368A2 (pt) 2017-06-27
HK1203935A1 (en) 2015-11-06
US20140148435A1 (en) 2014-05-29
AP2014008136A0 (en) 2014-12-31
CL2014003391A1 (es) 2015-07-10

Similar Documents

Publication Publication Date Title
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA40290A1 (fr) Agents immunorégulateurs
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
EA201591614A1 (ru) Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
MA32891B1 (fr) Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA38483A1 (fr) Inhibiteurs de l'ido
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
MA38090A1 (fr) Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA35444B1 (fr) Ligands du récepteur ep1
MA38091A2 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA37748A1 (fr) Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10